The success of Viagra initially fueled a boom for pharma, however recent shifts present a murky outlook for those considering a stake. Generic competitors are eroding earnings, and ongoing legal battles add more risk to the situation. While specific companies may still gain from complementary offerings, the overall direction suggests a cautious … Read More